Thrombolytic therapy for acute myocardial infarction

Fred L. Meister, Kathleen A. Stringer, Sarah A. Spinler, Edgar Gonzalez, Robert L. Talbert, Bruce Weiner, Rawley M. Guerrero, Richard Smith

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Numerous factors must be considered when determining the formulary status of thrombolytic agents for the treatment of acute myocardial infarction. Defined treatment options, predicted outcomes, and the economic consequences of this disorder continue to evolve from clinical trials. Pharmacists have a major role in delivering patient care, with responsibility for evaluating, procuring, and monitoring thrombolytic agents and drug therapy in general. By participating in the development and implementation of treatment guidelines, evaluating economic and therapeutic outcomes, providing timely optimal drug therapy, and educating health care providers and the public, they contribute significantly to the health care team.

Original languageEnglish (US)
Pages (from-to)686-698
Number of pages13
JournalPharmacotherapy
Volume18
Issue number4
Publication statusPublished - Jul 1 1998

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Meister, F. L., Stringer, K. A., Spinler, S. A., Gonzalez, E., Talbert, R. L., Weiner, B., ... Smith, R. (1998). Thrombolytic therapy for acute myocardial infarction. Pharmacotherapy, 18(4), 686-698.